Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Mar 1, 2026 to Dec 1, 2026v13
  2. Primary and study completion dates pushed to Mar 1, 2026v12
  3. Primary completion date: Jan 1, 2025 to Jun 1, 2025
    • Study completion date: Jan 1, 2025 to Dec 1, 2025
    v11
  4. Primary and study completion dates: May 1, 2024 to Jan 1, 2025v10
  5. Primary and study completion dates: Apr 1, 2024 to May 1, 2024v9
Show 7 earlier versionsHide 7 earlier versions
  1. Start date: Feb 10, 2020 to Apr 8, 2020v8
  2. Primary and study completion dates: Apr 1, 2023 to Apr 1, 2024v7
  3. Primary and study completion dates: Feb 28, 2023 to Apr 1, 2023v6
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 306 of 306 sites
    v5
  5. Re-verified, no change to tracked fieldsv4
  6. Study sites: 90 to 306v3
  7. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 90
    • Start date changed from estimate of Mar 7, 2020 to Feb 10, 2020
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II LUNG-MAP treatment trial studies how well selpercatinib works in treating patients with RET fusion-positive non-small cell lung cancer that is stage IV or has come back (recurrent). Selpercatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Trial Details
NCT Number NCT04268550
Lead Sponsor SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Related terms Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Enrollment 124 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov